UK’s NIHR aims to bring commercial research into primary care
The UK’s National Institute for Health and Care Research (NIHR) has announced plans to establish 14 centres to expand commercial research delivery and improve access to clinical trials.
As revealed in the announcement, NIHR has awarded more than £14 million ($19 million) to GP-led primary care organisations across England. The investment will establish 14 new NIHR Primary Care Commercial Research Delivery Centres (PC-CRDCs), funded through a public-private partnership between the government and the pharmaceutical industry’s Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) Investment Programme.
The plan, seen to be aligned with the UK government’s health and growth missions, will use the PC-CRDCs to support the shift of research and care from hospitals into community settings. It is hoped they will enhance access to clinical trials for people across England, particularly those in underserved groups and communities experiencing the greatest burden of ill health.
By ensuring fairer access to cutting-edge treatments and innovations such as medicines and vaccines through research, the centres aim to help people live healthier, longer lives. The plan could enhance the UK’s capacity and capability to deliver commercial clinical trials within primary care, supporting the UK’s aim to be a global leader in commercial clinical research delivery.
“This government wants to put the UK at the forefront of the revolution in life sciences and med tech, marrying our best scientific minds with the best minds in our NHS,” said Zubir Ahmed, Health Innovation Minister. “These centres will help turbocharge Britain’s medical research and improve patient care, as part of our 10 Year Health Plan.
“Through these new centres we will be able to extend commercial research delivery from the hospitals to the high street,” added Professor Lucy Chappell, Chief Scientific Adviser to the Department of Health and Social Care and CEO of the NIHR. “Patients will be able to take part in trials in their local communities, making it easier for them to get access to innovative treatments and technologies. This will allow a wider range of people to take part in research and accelerate delivery of commercial trials by supporting participation.”
The role of PC-CRDCs
Under the plans, the PC-CRDCs will accelerate the delivery of commercial clinical trials in primary care with gold standard set-up times and performance, through standardised costing, contracting, and dedicated staff and facilities with consistency of practice. They will also act as hubs to support decentralisation and diversification of clinical trial delivery and will contribute to an increase in research inclusion to ensure people from all eligible communities can participate in commercial clinical trials.
The PC-CRDCs will form part of the NIHR-funded Commercial Research Delivery Centre (CRDC) UK Network, alongside the 21 CRDCs established in April 2025. Each PC-CRDC will engage with primary care sites within the CRDC Network, particularly those located in their immediate vicinity, fostering local collaboration and maximising impact.
“This marks a significant step forward in strengthening our national research infrastructure and ensuring that commercial studies can be delivered efficiently and equitable across all parts of the country,” said Professor Melanie Davies, CRDC UK Network Director.
“Primary care plays a vital role in making research accessible to diverse communities and in supporting earlier diagnosis, prevention and innovation at scale. These new centres will work closely with regional and national partners to bring cutting-edge industry research opportunities closer to where people live, helping the UK remain a global leader in clinical research.”
Bruno Quinney, Content Team, DDW
